𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination Chemotherapy With Cisplatin and Peplomycin in Squamous Cell Carcinoma of the Head and Neck

✍ Scribed by Inuyama, Yukio; Fujii, Masato; Tanaka, Juichi; Takaoka, Tetsuro; Hosoda, Hyonosuke; Kohno, Naoyuki; Saito, Shigeji

Book ID
122020634
Publisher
Elsevier Science
Year
1986
Tongue
English
Weight
518 KB
Volume
13
Category
Article
ISSN
0385-8146

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combination chemotherapy with cisplatin,
Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in advanced squamous cell carcinoma of the head and neck
✍ Marcel Rozencweig; Pierre Dodion; Uta Bruntsch; Walter Gallmeier; Michel Clavel; πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 547 KB

A combination of cisplatin, methotrexate, bleomycin, and vincristine (CABO) was assessed in advanced epidermoid head and neck cancer. Among 72 patients with recurrent or metastatic disease and measurable lesions, there were 9 complete and 27 partial responses for an overall response rate of 50%. The

Combination chemotherapy for advanced sq
Combination chemotherapy for advanced squamous cell carcinoma of the head and neck
✍ Coker, Donald D. ;Elias, E. George ;Chretien, Paul B. ;Gray, William C. ;Coleman πŸ“‚ Article πŸ“… 1981 πŸ› Wiley (John Wiley & Sons) βš– 639 KB

## Abstract Fifty‐one patients (32 previously untreated, 19 previously treated) with advanced squamous cell carcinoma of the head and neck received a single course of combination chemotherapy consisting of high dose __cis__‐platinum (DDP), bleomycin (Bleo), Β± high dose methotrexate (MTX). Thirty‐th

Combination chemotherapy with methotrexa
Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck
✍ M. Clavel; F. Cognetti; P. Dodion; J. Wildiers; R. Rosso; A. Rossi; B. Gignoux; πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 449 KB πŸ‘ 2 views

## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot